Boule Diagnostics (BOUL) Q4 2023 earnings summary

Executive summary

• Q4 total sales growth was -1%, while organic growth reached 4.3%; growth came from European veterinary sales and Asian instrument sales.

• Strong operating cash flow and working-capital improvements supported the quarter; the 2024 focus is further efficiency and working-capital optimization.

Financial highlights

• Q4 net sales were SEK 148.1M versus SEK 149.2M; reported YoY growth was -1%.

• Gross margin was 45%, flat YoY; EBIT was SEK 10.5M versus SEK 10.0M and EBIT margin was 7.1% versus 6.7%.

• EBIT adjusted for one-off costs was SEK 15M, equivalent to a 10% margin.

• Operating cash flow was SEK 29.2M versus SEK 13.3M.

Outlook and guidance

• BM950 regulatory submission is planned during 2024, with sales growth expected in 2025.

• Long-term financial targets: operating margin above 15%, sales growth above 10%, and net debt/EBIT below 3x.

• 2024 priorities include optimizing working capital and production efficiency, growing the veterinary business, and investing in OEM consumables.